Mawi DNA Technologies Announces Partnership with FUJIFILM
Mawi DNA Technologies (Mawi) has signed a distribution agreement with FUJIFILM Wako Pure Chemical Corporation, a leader in the biomedical industry, to deliver Mawi’s iSWAB biosampling technologies to Japan.
“The collaboration with FUJIFILM Wako to provide iSWAB Microbiome-EL sample collection tubes for molecular testing of COVID-19 by PCR and LAMP based assay allows us to offer a valuable solution in the Japanese market,” said Atsushi Yanai, Asia Pacific Business Development at Mawi. “Being able to offer the collection without the need for an RNA Extraction step complements the WAKO Genomics product range, a valuable solution in the Japanese market and to society.”
FUJIFILM will be an authorized agent and distributor for Mawi products in Japan to detect viruses such as COVID-19.
“We are extremely grateful for the opportunity to partner with FUJIFILM, a respected organization with access to key customers in the Japanese market,” added Jerome David, VP of Sales and Marketing at Mawi. “We are confident that this initial partnership around our iSWAB-Microbiome-EL technology for extraction-less detection of SARS-CoV-2 RNA in patient samples will lead to additional opportunities for our entire portfolio of biosample collection products.”
About FUJIFILM Wako Pure Chemical Corporation
FUJIFILM Wako Pure Chemical Corporation is a comprehensive laboratory chemicals manufacturer contributing to a number of cutting-edge research fields. Over time, the company has developed and manufactured high-quality products and expanded its businesses to include specialty chemicals and clinical diagnostic reagents. For more information, visit https://www.fujifilm.com/ffwk/en.
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. The company’s flagship product iSWAB-DNA is the only sample collection product on the market proven to produce a high quality DNA sample with low bacterial DNA content. Mawi also supplies products for collection of RNA, microbiome, intact cells, and whole blood. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005344/en/
Contact information
Media Contact:
Susan Tellem, APR, RN, BSN
310-313-3444 x1, Susan@tellemgrodypr.com
Investors:
Jerome David, VP of Sales and Marketing
510-256-5186, j.david@mawidna.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Macrobond and FactSet Collaborate to Deliver Direct Access to Global Equity Data on a Single Integrated Research Platform23.10.2025 16:49:00 EEST | Press release
Macrobond, the leading provider of global economic and financial data and analytics, today announced a strategic integration with FactSet, a global digital platform and enterprise solutions provider. This collaboration provides Macrobond users with direct access to FactSet’s extensive equity and ETF datasets—including fundamentals, consensus estimates, market aggregates, and equity prices and returns —within the Macrobond platform. By combining Macrobond’s top-down macroeconomic insights with FactSet’s bottom-up company analysis, this collaboration delivers a uniquely complementary dataset that empowers clients to seamlessly integrate global economic trends with detailed security-level intelligence. This integration creates a seamless environment for economists, strategists, and analysts to analyze equity data with the efficiency and precision that define Macrobond’s approach to economic intelligence. The result enables enhanced decision-making, empowering users to drive smarter invest
Wolters Kluwer Ranks First in Dresner 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting Market Study23.10.2025 16:30:00 EEST | Press release
Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that its CCH® Tagetik Intelligent Platform has achieved the top position in the Dresner Advisory Services 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting (FCCR) Market Study. This marks the second straight year that Wolters Kluwer has earned the study’s number one ranking. Access the Dresner Advisory Services 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting (FCCR) Market Study. This study is part of Dresner Advisory Services’ ongoing research into the enterprise performance management (EPM) space and focuses specifically on performance management capabilities targeted at the finance function, including financial consolidation, close management and financial reporting. The study also identifies user trends, priorities, adoption patterns, and vendor performance, helping organizations make informed de
Andersen Consulting Collaborates with Acronotics to Deepen AI-led Digital Transformation Capabilities23.10.2025 16:30:00 EEST | Press release
Andersen Consulting strengthens its technology and business transformation capabilities through a Collaboration Agreement with Acronotics, a rapidly growing digital consulting firm headquartered in the UK with a presence in the U.S. and India. As a specialist in AI-led business transformation, Acronotics works with Fortune 500 companies to accelerate digital transformation by harnessing the power of AI. The firm has deep expertise across manufacturing, banking and financial services, retail, fast-moving consumer goods, and high-tech industries, with a strong focus on AI/ML, Generative AI, and RPA technology stacks. Acronotics delivers end-to-end services including the design, development, and implementation of Agentic AI and RPA-based process automation solutions. Leveraging its proprietary Automated Digital Worker Management platform, Radium.ai, the firm helps clients manage and monitor their digital workforce effectively. "Collaborating with Andersen Consulting enables us to scale gl
Crexendo and NUSO Partner to Deliver Global Cloud Communications Capabilities23.10.2025 16:15:00 EEST | Press release
NUSO, a leading provider of cloud communications service delivery, today announced it has been chosen by Crexendo®, Inc. (NASDAQ:CXDO), an award-winning software technology company that is a premier provider of cloud communication platform software and unified communication as a service (UCaaS) offerings, including voice, video, contact center, and managed IT services tailored to businesses of all sizes, to be a preferred carrier for the Crexendo cloud communications platform. The expanded partnership allows Crexendo platform licensees to offer cloud communications capabilities over NUSO’s global delivery network, unlocking new revenue opportunities for service providers. With NUSO’s carrier footprint in more than 40 countries, the Crexendo platform now offers global service delivery with industry-leading call quality, uptime, and emergency calling compliance. Platform providers can now offer global service delivery to over 6 million end users worldwide who rely on Crexendo’s Netsapien
SK pharmteco Boosts Domestic Peptide Scale-Up with Investment in California Facility23.10.2025 16:03:00 EEST | Press release
SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facility to expand and equip a new lab and CGMP-Kilo-scale facility for Solid-Phase Peptide Synthesis (SPPS) and purification. This expansion, combined with SK pharmteco’s industry-leading chromatography expertise and existing development and manufacturing capabilities in the United States, positions the company to meet the rising demand for U.S. peptide development and domestic clinical and commercial manufacturing. "The investment in our California facility represents a key milestone in our strategic growth and demonstrates an unwavering dedication to the domestic biopharma sector,” said Joerg Ahlgrimm, CEO of SK pharmteco. “Peptides are a vital and rapidly advancing therapeutic category. This project highlights our ongoing commitment to furthering their development and manufacturing.” “We are expanding our capacity to meet the increasing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom